Publications in collaboration with researchers from Masaryk University (18)

2024

  1. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

2023

  1. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  2. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

  3. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1383-1392

2022

  1. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

    Blood, Vol. 140, Núm. 26, pp. 2773-2787

2020

  1. Dissection of the Pre-Germinal Center B-Cell Maturation Pathway in Common Variable Immunodeficiency Based on Standardized Flow Cytometric EuroFlow Tools

    Frontiers in Immunology, Vol. 11

  2. EuroFlow Standardized Approach to Diagnostic Immunopheneotyping of Severe PID in Newborns and Young Children

    Frontiers in Immunology, Vol. 11

  3. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination

    Leukemia, Vol. 34, Núm. 2, pp. 589-603

2019

  1. CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase

    Leukemia, Vol. 33, Núm. 2, pp. 518-558

  2. Defects in memory B-cell and plasma cell subsets expressing different immunoglobulin-subclasses in patients with CVID and immunoglobulin subclass deficiencies

    Journal of Allergy and Clinical Immunology, Vol. 144, Núm. 3, pp. 809-824

  3. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study

    The Lancet Haematology, Vol. 6, Núm. 12, pp. e638-e649

  4. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS

    Leukemia, Vol. 33, Núm. 9, pp. 2254-2265

  5. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study

    Leukemia, Vol. 33, Núm. 9, pp. 2241-2253

2017

  1. Next-generation sequencing in chronic lymphocytic leukemia: Recent findings and new horizons

    Oncotarget, Vol. 8, Núm. 41, pp. 71234-71248

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2013

  1. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma

    Journal of Clinical Oncology, Vol. 31, Núm. 2, pp. 247-255

2012

  1. Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders

    Haematologica, Vol. 97, Núm. 8, pp. 1272-1277

2011

  1. Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)

    Blood, Vol. 118, Núm. 17, pp. 4519-4529